Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan | Republic Business

Advertisement

Republic Business

PwC invests in China despite record fine | Bajaj Housing Finance shares more than double | UK housing market gains steam from BoE rate cut |

Published 11:08 IST, August 29th 2024

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon Biologics has inked a pact with Janssen to launch a biosimilar medication for the treatment of autoimmune diseases in Europe, UK, Canada, and Japan.

News
2 min read

Reported by: Press Trust Of India

Follow:

Zolgensma injection

Representative | Image: Pixabay/Representative

Listen to this article
2 min read

Advertisement

11:08 IST, August 29th 2024